Lung Cancer

Tepotinib (Tepmetko) has been approved in Japan for the treatment of patients with non–small cell lung cancer harboring MET exon 14 skipping alterations.

In a wide-ranging discussion, Alexander Drilon, MD; Julia Rotow, MD; Thomas E. Stinchcombe, MD; and Ashish Saxena, MD, PhD, provide expert insight on developments in ALK-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, discusses the design and findings of an analysis examining the role of TMB as a predictive biomarker for pembrolizumab-based therapy in NSCLC.

Gregory A. Otterson, MD, discusses the utility of immunotherapy in squamous non–small cell lung cancer and targeted the evolution of targeted therapy in biomarker-driven disease.

Hui-Zi Chen, MD, PhD, discusses the use of immunotherapy in ES-SCLC and the work being done to identify mechanisms of resistance to frontline therapy.

Advanced, recurrent, and metastatic NSCLC is often associated with poor prognosis, and treatment is aimed to extend survival and provide symptom management.

Erin M. Bertino, MD, discusses the current treatment landscape and next steps in the EGFR-mutant NSCLC paradigm.

Terence M. Williams, MD, PhD, discusses the impact of the PACIFIC trial on stage III NSCLC and how the hunt for prognostic biomarkers is underway across the lung cancer paradigm.

Balazs Halmos, MD, MA, discusses the advances that have been made in the treatment of patients with metastatic non–small cell lung cancer, ongoing biomarker research, and the importance of molecular testing.

David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.

Terence T. Sio, MD, MS, discusses the utility of proton therapy in lung cancer.

The Chinese National Medical Products Administration has approved almonertinib (Ameile; HS-10296) for the treatment of patients with EGFR T790M mutation–positive non–small cell lung cancer who have progressed on or after other EGFR TKI therapy.

Anastasios Dimou, MD, discusses available and emerging treatment options and approaches for patients with oncogenic-driven lung cancer.

We recently traveled to Summit, New Jersey for a State of the Science Summit on Lung Cancer, which featured insights from Memorial Sloan Kettering Cancer Center faculty.

Chad Cherington, MD, discusses groundbreaking developments and critical next steps across the spectrum in lung cancer.

Combining durvalumab with standard frontline chemotherapies showed a sustained overall survival benefit in patients with extensive-stage small cell lung cancer, but a regimen of durvalumab, chemotherapy, and tremelimumab did not boost OS.

Balazs Halmos, MD, discusses the implications of the emergence of osimertinib in the frontline treatment of patients with EGFR-mutated non–small cell lung cancer, the efforts being made to address resistance to the third-generation EGFR TKI, and the promise of circulating tumor DNA in the space.

Panayiotis S. Savvides, MD, discusses the results of the KEYNOTE-407 and IMpower131 trials and how the data have impacted the treatment of patients with stage IV squamous non–small cell lung cancer.

Jonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.

Chad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.

Luis E. Raez, MD, discusses the role of liquid biopsies in newly diagnosed patients with lung cancer.

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.

The FDA has granted a breakthrough therapy designation to JNJ-61186372 for the treatment of patients with EGFR-positive metastatic non–small cell lung cancer who harbor exon 20 insertion mutations, and whose disease has progressed on or after platinum-based chemotherapy.

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

Michael K. Gould, MD, MS, discusses pivotal lung cancer screening trials and their impact on clinical practice.

Ronald B. Natale, MD, medical director, Clinical Lung Cancer Program and assistant clinical professor of medicine, Cedars-Sinai, discusses the utility of PD-L1 expression and tumor mutational burden (TMB) in lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer

Kavitha Ramchandran, MD, discusses considerations as patients with thoracic malignancies enter palliative care.

Zofia Piotrowska, MD, MHS, discusses the patient populations eligible to receive osimertinib as treatment for lung cancer.